

Beverly Moy

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8842980/beverly-moy-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

151
papers

3,857
citations

31
h-index

61
g-index

168
ext. papers

5,104
ext. citations

5.1
avg, IF

5.28
L-index

#	Paper	IF	Citations
151	Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 367-377	21.7	339
150	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1688-1700	21.7	328
149	Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3307-29	2.2	185
148	Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , 2016 , 2, 1477-1486	13.4	175
147	TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1081-1089	2.2	159
146	Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2142-50	2.2	155
145	Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With \geq HER2-Directed Regimens: Phase III NALA Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3138-3149	2.2	150
144	Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. <i>Clinical Cancer Research</i> , 2020 , 26, 2838-2848	12.9	132
143	Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2016 , 34, 945-52	2.2	121
142	Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1868-1875	2.2	120
141	Lapatinib: current status and future directions in breast cancer. <i>Oncologist</i> , 2006 , 11, 1047-57	5.7	120
140	Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3621-7	2.2	118
139	Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. <i>Lancet, The</i> , 2020 , 395, 817-827	40	116
138	American Society of Clinical Oncology policy statement: opportunities in the patient protection and affordable care act to reduce cancer care disparities. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3816-24	2.2	105
137	Lapatinib-associated toxicity and practical management recommendations. <i>Oncologist</i> , 2007 , 12, 756-65	5.7	91
136	Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3978-3986	3.2	90
135	NIMG-63. ADVANCED IMAGING FOR ASSESSING VOLUMETRIC RESPONSES IN BRAIN METASTASES TREATED WITH CHECKPOINT BLOCKADE. <i>Neuro-Oncology</i> , 2018 , 20, vi190-vi190	1	78

134	Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations. <i>Oncologist</i> , 2017 , 22, 1039-1048	5.7	76
133	Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. <i>Journal of Clinical Oncology</i> , 2015 , 33, 340-8	2.2	67
132	Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with \geq 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1002-1002	2.2	61
131	Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 93, 622-30	4	59
130	Barriers to repeat mammography: cultural perspectives of African-American, Asian, and Hispanic women. <i>Psycho-Oncology</i> , 2006 , 15, 623-34	3.9	56
129	Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. <i>Clinical Breast Cancer</i> , 2021 , 21, 80-91.e7	3	52
128	Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches. <i>Clinical Cancer Research</i> , 2006 , 12, 4790-3	12.9	49
127	Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016 , 2, 29-36	13.4	48
126	Financial Burden of Cancer Clinical Trial Participation and the Impact of a Cancer Care Equity Program. <i>Oncologist</i> , 2016 , 21, 467-74	5.7	41
125	AR Expression in Breast Cancer CTCs Associates with Bone Metastases. <i>Molecular Cancer Research</i> , 2018 , 16, 720-727	6.6	37
124	Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 511-511	2.2	35
123	Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. <i>Nature Medicine</i> , 2020 , 26, 1280-1284	50.5	34
122	Distribution and Patterns of Industry-Related Payments to Oncologists in 2014. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	32
121	Addressing Financial Barriers to Patient Participation in Clinical Trials: ASCO Policy Statement. <i>Journal of Clinical Oncology</i> , 2018 , JCO1801132	2.2	29
120	TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1005-1005	2.2	28
119	American Society of Clinical Oncology policy statement on medicaid reform. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4162-7	2.2	25
118	TEACH: Tykerb evaluation after chemotherapy. <i>Clinical Breast Cancer</i> , 2007 , 7, 489-92	3	25
117	Patient navigator programs, cancer disparities, and the patient protection and affordable care act. <i>Oncologist</i> , 2011 , 16, 926-9	5.7	23

116	Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. <i>Breast Cancer Research</i> , 2015 , 17, 56	8.3	21
115	Hemodynamic signature of breast cancer under fractional mammographic compression using a dynamic diffuse optical tomography system. <i>Biomedical Optics Express</i> , 2013 , 4, 2911-24	3.5	21
114	Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer. <i>Oncologist</i> , 2014 , 19, 348-9	5.7	17
113	Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers. <i>Breast Cancer Research and Treatment</i> , 2016 , 155, 569-78	4.4	16
112	A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1057-1057	2.2	16
111	Normalization of compression-induced hemodynamics in patients responding to neoadjuvant chemotherapy monitored by dynamic tomographic optical breast imaging (DTObI). <i>Biomedical Optics Express</i> , 2017 , 8, 555-569	3.5	15
110	A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017 , 163, 535-544	4.4	14
109	The impact of industry on oncology research and practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015 , 130-7	7.1	14
108	Blood-based monitoring identifies acquired and targetable driver mutations in endocrine-resistant metastatic breast cancer. <i>Npj Precision Oncology</i> , 2019 , 3, 18	9.8	13
107	Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic. <i>New England Journal of Medicine</i> , 2020 , 383, 262-272	59.2	12
106	Geriatric oncology for the 21st century: a call for action. <i>Journal of Oncology Practice</i> , 2014 , 10, 241-3	3.1	12
105	Debating the oncologist's role in defining the value of cancer care: our duty is to our patients. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4039-41	2.2	12
104	Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 508-508	2.2	12
103	PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial. <i>Breast Cancer Research</i> , 2019 , 21, 39	8.3	11
102	Correlation between financial relationships with commercial interests and research prominence at an oncology meeting. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2678-84	2.2	11
101	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3938-3958	2.2	11
100	Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. <i>Clinical Breast Cancer</i> , 2020 , 20, 145-151.e2	3	10
99	Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer. <i>Oncologist</i> , 2014 , 19, 346-7	5.7	9

98	Phase Ib trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy and a CDK4/6 inhibitor for patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) (TAKTIC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1066-1066	2.2	9
97	Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). <i>Breast Cancer Research and Treatment</i> , 2019 , 176, 303-310	4.4	8
96	A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry. <i>Breast Cancer Research and Treatment</i> , 2020 , 183, 515-524	4.4	8
95	Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018 , 172, 733-740	4.4	8
94	Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study. <i>Cancer</i> , 2015 , 121, 1937-48	6.4	7
93	Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer. <i>European Journal of Cancer</i> , 2015 , 51, 685-96	7.5	7
92	Identification of Somatically Acquired Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 4852-4862	12.9	7
91	Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial. <i>Oncologist</i> , 2021 , 26, e1327-e1338	5.7	7
90	Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update Summary. <i>Journal of Oncology Practice</i> , 2017 , 13, 822-824	3.1	6
89	Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102647	2.2	6
88	Expanding Access to Cancer Clinical Trials for Patients With Mental Illness. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1524-1528	2.2	5
87	Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer. <i>BMC Cancer</i> , 2020 , 20, 347	4.8	5
86	Impact of Timing on Measurement of Decision Quality and Shared Decision Making: Longitudinal Cohort Study of Breast Cancer Patients. <i>Medical Decision Making</i> , 2019 , 39, 642-650	2.5	5
85	Medical integrity up in smoke? Conflicts of interest and the lung cancer screening controversy. <i>Oncologist</i> , 2008 , 13, 474-6	5.7	5
84	FGFR gene amplification and response to endocrine therapy in metastatic hormone receptor positive (HR+) breast cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1013-1013	2.2	5
83	Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer.. <i>JCO Precision Oncology</i> , 2020 , 4, 1246-1262	3.6	5
82	Standardized activities for lay patient navigators in breast cancer care: Recommendations from a citywide implementation study. <i>Cancer</i> , 2019 , 125, 4532-4540	6.4	4
81	Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. <i>European Journal of Cancer</i> , 2016 , 56, 85-92	7.5	4

80	Survivorship Model of Care: Development and Implementation of a Nurse Practitioner-Led Intervention for Patients With Breast Cancer?. <i>Clinical Journal of Oncology Nursing</i> , 2017 , 21, E99-E105	1.1	4
79	Financial burden in adult cancer survivors: Care affordability and accessibility.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 6535-6535	2.2	4
78	Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1028-1028	2.2	4
77	Value of cancer care: ethical considerations for the practicing oncologist. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014 , e146-9	7.1	4
76	Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021 , 1-8	7.3	4
75	Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities. <i>Oncologist</i> , 2021 , 26, 827-834	5.7	4
74	Randomized Trial of a Palliative Care Intervention to Improve End-of-Life Care Discussions in Patients With Metastatic Breast Cancer.. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022 , 20, 136-143	7.3	3
73	Tumor genomics and response to CDK 4/6 inhibitors for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1046-1046	2.2	3
72	Issues in Breast Cancer Survivorship: Optimal Care, Bone Health, and Lifestyle Modifications. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016 , 35, e22-9	7.1	3
71	Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021 , 19, 797-804	7.3	3
70	Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 5818-5827	12.9	3
69	Impact of hormone receptor (HR) status on clinicopathological features, patterns of recurrence, and clinical outcomes among patients (pts) with human epidermal growth factor receptor-2 positive (HER2) breast cancer (BC) in the National Comprehensive Cancer Network (NCCN).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 500-500	2.2	2
68	Impact of PIK3CA tumor mutation on the association of aspirin or NSAID use and time to breast cancer recurrence.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1521-1521	2.2	2
67	Randomized trial of a collaborative palliative and oncology care intervention to improve communication about end-of-life care in patients with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1008-1008	2.2	2
66	Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2- breast cancer (LEADER).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 531-531	2.2	2
65	Core elements of the patient protection and affordable care act and their relevance to the delivery of high-quality cancer care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012 , e4-8	7.1	2
64	Comparison of tissue genotyping (TG) vs circulating tumor DNA (ctDNA) for selection of matched therapy and impact on clinical outcomes among patients with metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1020-1020	2.2	2
63	Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer. <i>Radiation Oncology</i> , 2020 , 15, 198	4.2	2

62	Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 3404-3413	13.9	2
61	No Conflict, No Interest. <i>JAMA Oncology</i> , 2016 , 2, 1631-1632	13.4	1
60	The Elimination of Cancer Health Disparities: Are We Ready to Do the Heavy Lifting?. <i>Oncologist</i> , 2016 , 21, 1411-1413	5.7	1
59	Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 117-117	2.2	1
58	Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer: Phase 1b clinical trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS1106-TPS1106	2.2	1
57	Implementation of a brief screening tool to identify needs of cancer survivors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e23075-e23075	2.2	1
56	Comparison of the cell-free DNA genomics in patients with metastatic breast cancer (MBC) who develop brain metastases versus those without brain metastases.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1094-1094	2.2	1
55	Antibody drug conjugates for patients with breast cancer. <i>Current Problems in Cancer</i> , 2021 , 45, 100795	2.3	1
54	Genomic landscape of primary breast cancer in black vs. white women and association with tumor recurrence.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6553-6553	2.2	1
53	Association between treatment duration and overall survival in early-stage HER2+ breast cancer patients receiving extended adjuvant therapy with neratinib in the ExteNET trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 540-540	2.2	1
52	Feasibility of integrating the Outcomes4Me smartphone navigation application into the care of breast cancer patients (FIONA).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1570-1570	2.2	1
51	Implementation of a Brief Screening Tool to Identify Needs of Breast Cancer Survivors. <i>Clinical Breast Cancer</i> , 2021 , 21, e88-e95	3	1
50	Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer. <i>Npj Breast Cancer</i> , 2021 , 7, 103	7.8	1
49	Financial toxicity, symptom burden, illness perceptions, and communication confidence in cancer clinical trial participants.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 86-86	2.2	1
48	The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population. <i>Journal of Oncology Pharmacy Practice</i> , 2020 , 1078155220971751	1.7	0
47	Breast Cancer Index (BCI) and prediction of pathological complete response (pCR) to neoadjuvant chemotherapy in estrogen receptor positive (ER+) breast cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 576-576	2.2	0
46	Assessment of patient navigation programs for breast cancer patients across the city of Boston. <i>Supportive Care in Cancer</i> , 2021 , 1	3.9	0
45	Disparities in phase 1 cancer clinical trial enrollment. <i>Cancer</i> , 2021 , 127, 4464-4469	6.4	0

44	Implementing a patient navigation program to improve adherence with cancer treatment for community health center patients newly diagnosed with cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 103-103	2.2	0
43	NIMG-05. ADVANCED IMAGING TO ASSESS LONGITUDINAL VASCULAR CHANGES IN BRAIN METASTASES TREATED WITH CHECKPOINT INHIBITION. <i>Neuro-Oncology</i> , 2020 , 22, ii147-ii147	1	
42	Addressing financial concerns of cancer clinical trial participants: Longitudinal outcomes of an equity intervention.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 6566-6566	2.2	
41	Considering cost and value with patients in clinic.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e18905-e18905	2.2	
40	Delays in initial breast cancer treatment among black and white women in Boston.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e18620-e18620	2.2	
39	Molecular alterations in the Ras-Raf-Erk (MAPK) pathway in metastatic hormone receptor positive (HR+)/HER2- breast cancer: Incidence and impact on clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1021-1021	2.2	
38	Working together in cancer care: An academic community partnership for a diverse patient population.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 10525-10525	2.2	
37	Medical oncologists' perceptions of clinical trials for underrepresented populations.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e19062-e19062	2.2	
36	Factors associated with frequent insomnia among breast cancer survivors.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e24098-e24098	2.2	
35	Advanced imaging to assess longitudinal vascular changes in brain metastases treated with immune checkpoint inhibition.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2529-2529	2.2	
34	Emerging trends in type of chemotherapy (CT) received among patients (pts) with stage I breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 522-522	2.2	
33	Alleviating financial burden for cancer patients in clinical trials.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10-10	2.2	
32	Financial burden of cancer clinical trials: Impact of an equity program intervention.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6501-6501	2.2	
31	Hospitalizations and emergency department use in cancer clinical trial patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 160-160	2.2	
30	Palliative care consultation for patients enrolled in cancer clinical trials.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 139-139	2.2	
29	Prospective study of the financial burden of cancer clinical trial patients referred to a cancer care equity program (CCEP).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e18056-e18056	2.2	
28	Tolerability and effectiveness of pertuzumab-containing neoadjuvant (NA) regimens vs. AC-TH for HER2-positive (+) localized breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 586-586	2.2	
27	Breast cancer care redesign as an approach to streamline survivorship care: Outcomes and challenges.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9-9	2.2	

26	Are NCI-designated cancer centers websites linguistically accessible?. <i>Journal of Clinical Oncology</i> , 2017 , 35, e18078-e18078	2.2
25	Association between financial relationships with commercial interests and research merit at the ASCO Annual Meeting (AM).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 6095-6095	2.2
24	Financial relationships with commercial interests (COI) among abstracts at the ASCO Annual Meeting.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 6128-6128	2.2
23	Lapatinib in HER2+ early breast cancer: Quality of life analysis.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 604-604	2.2
22	Adjuvant lapatinib in women with early-stage HER2-positive breast cancer (HER2+ BC): Analysis of the hormone receptor-negative subgroup of the intent-to-treat (ITT) population of the TEACH trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 596-596	2.2
21	Time trends in the use of adjuvant chemotherapy (CTX) and outcomes in women with T1N0 breast cancer (BC) in the National Comprehensive Cancer Network (NCCN).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1006-1006	2.2
20	Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 630-630	2.2
19	Risk perceptions in localized breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9534-9534	2.2
18	Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 533-533	2.2
17	NCIC CTG MAP.3: Symptoms and quality of life (QoL) among racial/ethnic minority women taking the aromatase inhibitor (AI) exemestane (EXE) for breast cancer risk reduction.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 6557-6557	2.2
16	Impact of single and dual neoadjuvant HER2-directed therapy on clinical outcomes among patients with HER2-positive breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 647-647	2.2
15	Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 145-145	2.2
14	Neoadjuvant single and dual HER2 blockade among patients with localized HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 147-147	2.2
13	Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 167-167	2.2
12	Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and prior HER2-directed regimens. <i>Breast Cancer Research and Treatment</i> , 2021 , 188, 449-458	4.4
11	Advanced imaging to assess longitudinal vascular changes in brain metastases treated with checkpoint inhibition.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3059-3059	2.2
10	Illness perceptions, financial toxicity, symptom burden, and survival in cancer clinical trial (CCT) participants.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 160-160	2.2
9	Abstract P3-13-01: Association of polygenic risk score with 2 year risk of poor prognosis breast cancer. <i>Cancer Research</i> , 2022 , 82, P3-13-01-P3-13-01	10.1

- 8 Abstract P3-09-11: Clinical characteristics associated with BRCA1/2 mutations identified on routine tumor tissue genotyping in metastatic breast cancer. *Cancer Research*, **2022**, 82, P3-09-11-P3-09-11 10.1
- 7 Abstract P1-18-22: AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigation. *Cancer Research*, **2022**, 82, P1-18-22-P1-18-22 10.1
- 6 Abstract P1-14-02: Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2- breast cancer (LEADER, part 1). *Cancer Research*, **2022**, 82, P1-14-02-P1-14-02 10.1
- 5 Abstract P4-12-08: Accuracy of Patient Self-Reported Breast Cancer Disease Characteristics Compared to the Medical Record in a Trial of the Outcomes4MeDigital Health App. *Cancer Research*, **2022**, 82, P4-12-08-P4-12-08 10.1
- 4 Abstract P3-23-02: Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer receiving CDK 4/6 inhibitors. *Cancer Research*, **2022**, 82, P3-23-02-P3-23-02 10.1
- 3 Abstract PD5-11: Pilot study to assess prolonged nightly fasting in breast cancer survivors (LONGFAST). *Cancer Research*, **2022**, 82, PD5-11-PD5-11 10.1
- 2 Abstract P3-16-01: Population effectiveness model of the consequences of recurrence after trastuzumab emtansine (T-DM1) treatment among U.S. patients with high-risk HER2+ early-stage breast cancer (ESBC). *Cancer Research*, **2022**, 82, P3-16-01-P3-16-01 10.1
- 1 CLO22-033: Clinicopathologic and Sociodemographic Factors Associated With Late Relapse Triple Negative Breast Cancer. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2022**, 20, CLO22-033 7.3